Panacea Acquisition II (Panacea Acquisition II) Interest Expense : $0.00 Mil (TTM As of Dec. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Panacea Acquisition II Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Panacea Acquisition II's interest expense for the three months ended in Dec. 2022 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2022 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Panacea Acquisition II's Operating Income for the three months ended in Dec. 2022 was $ -0.22 Mil. Panacea Acquisition II's Interest Expense for the three months ended in Dec. 2022 was $ 0.00 Mil. Panacea Acquisition II has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Panacea Acquisition II Interest Expense Historical Data

The historical data trend for Panacea Acquisition II's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Panacea Acquisition II Interest Expense Chart

Panacea Acquisition II Annual Data

Trend

Dec21

Dec22

Interest Expense

Panacea Acquisition II Quarterly Data
	Jan21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Interest Expense	Get a 7-Day Free Trial			-	-	-	-	-

Panacea Acquisition II Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Panacea Acquisition II (NAS:PANA) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Panacea Acquisition II's Interest Expense for the three months ended in Dec. 2022 was $0.00 Mil. Its Operating Income for the three months ended in Dec. 2022 was $-0.22 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2022 was $0.00 Mil.

Panacea Acquisition II's Interest Coverage for the quarter that ended in Dec. 2022 is calculated as

Panacea Acquisition II had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Panacea Acquisition II (Panacea Acquisition II) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Panacea Acquisition Corp II (NAS:PANA) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

357 Tehama Street, Floor 3, San Francisco, CA, USA, 94103

Website

Panacea Acquisition Corp II is a blank check company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

Executives

Ecor1 Capital Fund Qualified, L.p.	director, 10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital, Llc	director, 10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Oleg Nodelman	director, 10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital Fund, L.p.	director, 10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Venture Opportunity Fund, Lp	director, 10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Biotech Opportunity Gp, Llc	director, 10 percent owner	1370 TRANCAS STREET, SUITE 176, NAPA CA 94558
Ecor1 Panacea Holdings Ii, Llc	director, 10 percent owner	357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Douglas E Williams	director	C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799
Douglas E. Giordano	director	C/O PFIZER INC., 235 EAST 42ND STREET, NEW YORK NY 10017
Nina S Kjellson	director	C/O INTERWEST PARTNERS, 2710 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Praveen P. Tipirneni	director	C/O MORPHIC HOLDING, INC.,, 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Sarah Marriott	director, officer: Secretary	C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Scott Perlen	officer: Chief Financial Officer	C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Caroline Stout	officer: Chief Investment Officer	C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Scott Platshon	officer: Chief Operating Officer	C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103